Skip to main content

The BBRC was the first center in Europe to begin the recruitment of the Novatis-led Generation S1 essay, in collaboration with Amgen and the Banner Alzheimer's Institute.

Started in 2015, its objective is to evaluate the efficacy of two drugs administered separately, CAD106 and CNP520, to delay the onset and progression of clinical symptoms associated with Alzheimer's disease.

The clinical trial is phase II and III, randomized, double blind, with placebo control, of two cohorts and parallel groups. Participants are people between 60 and 75 years old who are at the risk of developing symptoms due to age and genetic condition.

For 5 and 8 years, the participants will receive the placebo or one of the two treatments. On the one hand, CAD106 is an immunotherapy administered intravenously, and is aimed at producing a biological response that helps eliminate beta amyloid plaques in the brain. On the other hand, CNP520 is a BACE inhibitor administered orally and designed to reduce amyloid beta production in the brain.

Participation in the study involves testing of Positron Emission Tomography (PET), brain magnetic resonance imaging and cognitive tests, among others. The trial plans to recruit 1,340 participants worldwide and is part of the Alzheimer's Prevention Initiative (API) program.
 

Generation S1 (Novartis)
BBRC was the first center in Europe to begin the recruitment of this trial